DelphX Announces Proposed Warrant Extension
MWN-AI** Summary
DelphX Capital Markets Inc. (TSXV: DELX; OTCQB: DPXCF), a prominent player in structured financial products, announced its intention to extend the exercise period for 3,904,166 share purchase warrants. Initially set to expire on January 30, 2026, DelphX aims to push this deadline back by one year to January 30, 2027, subject to approval from the TSX Venture Exchange. The warrants, which have an exercise price of $0.20 per share, were issued during a private placement on January 30, 2024. Aside from the extension, all other terms and conditions of these warrants will remain unchanged.
Notably, 1,208,333 of these warrants are held by related parties of DelphX, thus the extension qualifies as a "related party transaction." However, the company can benefit from exemptions concerning formal valuation and minority approval requirements, as the fair market value of the warrants does not exceed 25% of DelphX's market capitalization.
DelphX specializes in developing innovative structured products through its subsidiary, Quantem LLC. The company’s offerings include proprietary instruments such as Collateralized Put Options (CPOs) and Collateralized Reference Notes (CRNs), designed to secure investors against corporate bond downgrades and cryptocurrency losses, offering attractive returns while being fully collateralized by U.S. Bank.
As DelphX focuses on expanding its product suite and navigating the volatile crypto markets, the extension of the warrants may serve as an essential move to foster investor confidence and support its ongoing initiatives. Stakeholders are advised to consider potential risks associated with forward-looking statements within this announcement, including market dynamics and regulatory conditions.
MWN-AI** Analysis
DelphX Capital Markets Inc. (TSXV: DELX, OTCQB: DPXCF) has announced a proposed extension of the exercise period for 3,904,166 share purchase warrants, intending to push the expiration date from January 30, 2026, to January 30, 2027. This strategic move, subject to the approval of the TSX Venture Exchange, aims to provide existing warrant holders additional time to benefit from the warrants, particularly in light of DelphX's innovative structured products and market proposition.
Investors should consider the implications of this warranted extension. The share price is currently at $0.20, directly equating to the exercise cost of these warrants. The related-party nature of the transaction, with 1,208,333 warrants held by insiders, underscores a level of confidence from the company's leadership in its future prospects. This could signal to investors that those closest to the firm's operations believe that the stock might rise significantly above the $0.20 mark, making the warrants more valuable long-term.
Moreover, DelphX continues to innovate with its proprietary products like Collateralized Put Options (CPOs) and Collateralized Reference Notes (CRNs), which cater to the dual interests of fixed-income and cryptocurrency investors. The full collateralization of these products by U.S. Bank provides a safety net against the inherent risks present in the crypto market.
However, despite the potential upside, investors should throw caution to the wind. The company operates in a volatile environment influenced by economic conditions and regulatory nuances. As DelphX navigates these challenges, potential volatility may affect share price movements. Therefore, while the warrant extension presents an attractive opportunity, maintaining a vigilant appraisal of market conditions and company performance is prudent. Investors should weigh the risks versus the opportunities afforded by this strategic maneuver.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Toronto, Ontario, Feb. 17, 2026 (GLOBE NEWSWIRE) -- DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX"), a leader in the development of new classes of structured products, announces that it intends to seek approval of the TSX Venture Exchange to extend the exercise period of share purchase warrants.
DelphX intends to seek approval of the TSX Venture Exchange to extend the exercise period of 3,904,166 share purchase warrants, exercisable at $0.20 per common share (issued pursuant to a private placement announced January 30, 2024) by one year to January 30, 2027.
All other terms and conditions of the warrants will remain unchanged. The warrant extension is subject to acceptance by the TSX Venture Exchange.
A total of 1,208,333 warrants are held by parties who are considered to be "related parties" of DelphX Therefore, the amendment of Warrants constitutes a "related party transaction" as contemplated by Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions, and TSXV Policy 5.9 - Protection of Minority Security Holders in Special Transactions. However, the exemptions from formal valuation and minority approval requirements provided for can be relied upon as the fair market value of the Warrants does not exceed 25% of the market capitalization of DelphX.
About DelphX Capital Markets Inc.
DelphX is a technology and financial services company focused on developing and distributing the next generation of structured products. Through its special purpose vehicle, Quantem LLC, the Company enables broker-dealers to offer new private placement securities providing both fixed-income and cryptocurrency-based solutions. DelphX's proprietary securities include:
- Collateralized Put Options (CPOs), which provide secured protection against rating downgrades of corporate bonds and/or losses in cryptocurrency holdings; and
- Collateralized Reference Notes (CRNs), which enable investors to assume capped downgrade or cryptocurrency-loss exposure in exchange for attractive returns.
All CPOs and CRNs are fully collateralized and held in custody by U.S. Bank. These instruments are proprietary products created and owned by DelphX Capital Markets Inc.
For more information about DelphX, please visit www.delphx.com
George Wentworth, General Manager
DelphX Capital Markets Inc.
george.wentworth@delphx.com
(718) 509-2160
Forward-Looking Statements
This news release contains certain forward-looking statements, including statements regarding our business strategy and product development. Forward-looking statements involve risks and uncertainties, both known and unknown, that may cause actual results or events to be materially different from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions, regulatory uncertainties, and the demand for our products. The forward-looking statements in this news release are based on factors and assumptions regarding, among other things, the state of the capital markets, the ability of DelphX to successfully manage the risks inherent in pursuing business opportunities in the financial services industry and the volatile crypto market, and the ability of DelphX to obtain qualified staff, equipment and services in a timely and cost-efficient manner to develop its business. Although we believe that the assumptions underlying these forward-looking statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. Any forward-looking statement reflects information available to DelphX as of the date of this news release and, except as may be required by applicable laws, DelphX undertakes no intent or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or results or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FAQ**
How will the proposed extension of the exercise period for DelphX Capital Markets Inc. (DPXCF) warrants impact its market position and investor confidence in February 2026?
What are the potential risks associated with the business model of DelphX Capital Markets Inc. (DPXCF), particularly in relation to its focus on cryptocurrency-based structured products?
How does DelphX Capital Markets Inc. (DPXCF) plan to address the regulatory uncertainties mentioned in their release while pursuing new business opportunities in 2026?
Can you explain the significance of DelphX Capital Markets Inc. (DPXCF) being classified as a related party transaction under Multilateral Instrument 61-101, especially regarding investor protections?
**MWN-AI FAQ is based on asking OpenAI questions about Delphx Capital Markets Inc. (OTC: DPXCF).
NASDAQ: DPXCF
DPXCF Trading
0.0% G/L:
$0.033 Last:
30,000 Volume:
$0.033 Open:
